top of page

REPOSE

REPOTRECTINIB IN ROS1-POSITIVE NON-SMALL CELL LUNG CANCER PATIENTS WITH ACTIVE BRAIN METASTASIS

CLINICAL TRIAL DETAILS

A PHASE II STUDY ASSESSING SAFETY AND EFFICACY OF REPOTRECTINIB IN ROS1-POSITIVE NON-SMALL CELL LUNG CANCER PATIENTS WITH ACTIVE BRAIN METASTASIS (REPOSE STUDY).

REPOSE AT CLINICALTRIALS.GOV

COUNTRY

STATUS

TUMOR TYPE

PHASE

N

SITES

NSCLC BMs

​

20

II

Spain, Germany, Austria

Recruitment

TRIAL OVERVIEW

home_fondo_you_barra.jpg
Luzern_edited_edited_edited_edited_edite

PRESS RELEASE

home_fondo_you_barra.jpg

-

SCIENTIFIC IMPACT

home_fondo_you_barra.jpg

WCLC 2025 poster

BLOG ARTICLES RELATED

home_fondo_you_barra.jpg

-

TRIAL SITES

home_fondo_you_barra.jpg
-
Dr. Sofia Braga
Dr. Silvi Antolín
Dr. Escrivá de Romaní
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page